Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses When the Vaccine is Delivered by Electrical Impulses

A Phase 1 study of a preventive HIV vaccine show that a novel delivery mechanism known as electroporation helped to enhance the immunogenicity of the vaccine tested. Results were presented at the end of October at the AIDS Vaccine Conference in Paris, France. Please see the IAVI and Ichor Medical Systems, Inc. announcement below for more information.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account